Institut Pasteur has entered into a research and licensing pact with a Swizerland-based niche generics and molecules developer Stragen to develop pain management drug Opiorphin.
Opiorphin, a 5-amino acids peptide initially discovered from human saliva, was shown to be as efficient as morphine when tested in animal models of pain but without any of the adverse events typically associated with the reference molecules.
As per the terms of the agreement, Stragen is responsible for developing the drug and will incur its development cost.
Stragen has further got license from Institut Pasteur for signing royalty-bearing license agreement for Opiorphin.
Institut Pasteur will receive contingent payments linked with the good execution of the clinical development.
Stragen president Jean-Luc Tetard said the beauty of Opiorphin is that for the first time in pain management they are dealing with a natural compound from the human body which is expected to minimize toxicity and addictive effect.